Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.

TPS9113Background: Epidermal growth factor receptor(EGFR) mutations are one of the most common driver oncogenesin non-small cell lung cancer (NSCLC). While the presence of these mutations predict...